Valo Health to Participate in Financial Times US Pharma and Biotech Summit
News provided by
Share this article
BOSTON, April 29, 2021 /PRNewswire/
Valo Health, LLC (Valo), the technology company that is using human-centric data, machine learning computation and life science expertise to transform and accelerate the drug discovery and development process, today announced that David Berry, Ph.D., founder and Chief Executive Officer of Valo will participate in a panel discussion during the Financial Times US Pharma and Biotech Summit on Wednesday, May 5, 2021 at 11:30 AM ET.
The panel,
Navigating the pharma investment landscape, will focus on emerging investment trends in the areas of therapeutics, technology, and M&A.
Valo Health to Participate in Financial Times US Pharma and Biotech Summit
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Valo to Participate in Credit Suisse 2021 Healthcare Innovators Series: The Intersection of Drug Discovery, Drug Development and Artificial Intelligence
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share
Cedar, the maker of an intelligent patient billing and engagement platform, announced today a $200 million Series D round of funding headed by Tiger Global Management, with participation from prior backers including Andreessen Horowitz (a16z), Thrive Capital and Concord Health Partners. This brings the company s total fundraising haul to $350 million, it said, and its valuation to $3.2 billion.
Cedar said that its patient-friendly digital offering has helped quadruple its business throughout the course of 2020 and now engages with more than 300,000 patients per day. It said it will use the new money to push its product roadmap outside of its core financial engagement product and focus on patient engagement offerings such as pre-visit price transparency tools.